Association Between EGF, TGF-β1 and TNF-α Gene Polymorphisms and Hepatocellular Carcinoma

  • Shi, Hai-Zhou (Department of General Surgery, Binzhou Central Hospital, Binzhou medical College) ;
  • Ren, Peng (Department of General Surgery, Binzhou Central Hospital, Binzhou medical College) ;
  • Lu, Qing-Jun (Department of General Surgery, Binzhou Central Hospital, Binzhou medical College) ;
  • Niedrgethmnn, Marco (Surgical Clinic, University Hospital Mannheim) ;
  • Wu, Guo-Yang (Department of General Surgery, Zhongshan Hospital, Xiamen University)
  • Published : 2012.12.31


Introduction: Up to present, EGF $61^*A$/G, TGF-${\beta}1$-$509^*T$/C and TNF-${\alpha}$-$308^*A$/G gene polymorphisms have been analysed in other cancer entities than hepatocellular carcinoma (HCC). We here investigated the frequency of these gene polymorphisms among HCC patients. Materials and Methods: A total of 73 HCC patients and 117 cancer-free healthy people were recruited at the Surgical Department of Zhongshan Hospital. Genomic DNA was isolated from peripheral blood and gene polymorphisms were analyzed by PCR-RFLP. Results: The distribution of EGF $61^*G$/G homozygotes among HCC patients was more frequent than that in the control group (24.7% vs 11.1%, OR=2.618, 95%CI=1.195-5.738). In parallel, the frequency of the "G" allele in the HCC patient group was also higher than that in the control group (45.9% vs 33.3%, OR= 1.696, 95%CI=1.110-2.592). No difference could be found for the TGF-${\beta}1$-509 and TNF-${\alpha}$-308 genotypes. Conclusion: EGF $61^*G$/G genotype and G allele are significantly increased among patients with HCC. TGF-${\beta}1$-$509^*T$/C and TNF-${\alpha}$-$308^*A$/G gene polymorphisms are not related to this cancer entity.


Hepatocellular carcinoma;polymorphism;growth factor;EGF


  1. Kroeger KM, Carville KS, Abraham LJ (1997). The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol, 34, 391-99.
  2. Kim JY, Jung JH, Kim LH, Park BL, Shin HD(2003). Association of transforming growth factor-${\beta}1$ gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Experimental and molecular medicine, 35, 196-202.
  3. Korc M (2007). Pancreatic cancer-associated stroma production. Am J Surg, 194, 84-6.
  4. Luca AD, Carotenuto A, Rachiglio A, et al(2008). The role of the EGFR signaling in tumor microenvironment. J Cell Physiol, 214, 559-67.
  5. McCarron SL, Bateman AC, Theaker JM, Howell WM (2003). EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int J Cancer, 107, 673-5.
  6. Oh BR, Sasaki M, Perinchery G, et al (2000). Frequent genotype changes at -308 and 488 regions of the tumor necrosis factor-$\alpha$ (TNF-$\alpha$) gene in patients with prostate cancer. J Urol, 163, 1584-7.
  7. Sakao S, Tatsumi K, Igari H, et al (2002). Association of tumor necrosis factor-alpha gene promoter polymorphism with low attenuation areas on high-resolution CT in patients with COPD. Chest, 122, 416-20.
  8. Schulte CM, Goebell H, Roher HD, et al (2001). C-509T polymorphism in the TGF-$\beta$1 gene promoter: impact on Crohn's disease susceptibility and clinical course? Immunogenetics, 53, 178-82.
  9. Shahbazi M, Pravica V, Nasreen N, et al (2002). Association between functional polymorphism in EGF gene and malignant melanoma. Lancet, 359, 397-401.
  10. Shin A, Shu XO, Cai Q, Gao YT, Zheng W (2005). Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev, 14, 1567-70.
  11. Stuelten CH, DaCosta BS, Arany PR, et al (2005). Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-$\alpha$ and TGF-$\beta$. J Cell Sci, 118, 2143-53.
  12. Van HR, Ten TL, Eggermont AM (2006). TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist, 11, 397-408.
  13. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW (1997). Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA, 94, 3195-99.
  14. Wu GY, Hasenberg T, Magdeburg R, et al (2009). Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J Surgery, 33, 124-9.
  15. Yang JD, Roberts LR (2010). Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol, 7, 448-58.
  16. Balkwill F (2002). Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev, 13, 135-41.
  17. Bussink J, van der Kogel AJ, Kaanders JH (2008). Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol, 9, 288-96.
  18. Chouchane L, Ahmed SB, Baccouche S, Remadi S (1997). Polymorphism in tumor necrosis factor-$\alpha$ promoter region and in the heat shock protein 70 genes associated with malignant tumors. Cancer, 80, 1489-96.<1489::AID-CNCR17>3.0.CO;2-1
  19. Costa BM, Ferreira P, Costa S, et al (2007). Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res, 13, 2621-6.
  20. Derynck R, Akhurst RJ, Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 29, 117-29.
  21. Friess H, Guo XZ, Nan BC, Kleeff O, Buchler MW(1999). Growth factors and cytokines in pancreatic carcinogenesis. Ann NY Acad Sci, 880, 110-21.
  22. Grainger DJ, Heathcote K, Chiano M, et al (1999). Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet, 8, 93-7.
  23. Ghaneh P, Kawesha A, Evans JD (2002). Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg, 9, 1-11.
  24. Hamai Y, Matsumura S, Matsusaki K, et al (2005). A single nucleotide polymorphism in the 5' untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer. Pathobiology, 72, 133-8.
  25. Ikeguchi M, Iwamoto A, Taniguchi K, Katano K, Hirooka Y (2005). The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma. J Exp Clin Cancer Res, 24, 415-21.
  26. Jang WH, Yang YI, Yea SS, et al (2001). The -238 tumor necrosis factor-$\alpha$ promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett, 166, 41-6.
  27. Jemal A, Murray T, Ward E, et al (2005). Cancer statistics, 2005. CA Cancer J Clin, 55, 10-30.
  28. Jakowlew SB (2006). Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev, 25, 435-57.
  29. Jeng JE, Tsai JF, Chuang LY, et al(2007). Tumor necrosis factoralpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia, 9, 987-92.

Cited by

  1. A/G Polymorphism and Hepatocellular Carcinoma Risk: a Meta-Analysis vol.16, pp.7, 2015,
  2. Host nucleotide polymorphism in hepatitis B virus-associated hepatocellular carcinoma vol.8, pp.10, 2016,
  3. Tumor Necrosis Factor-α-308 G/A Polymorphisms and Risk of Hepatocellular Carcinoma: A Meta-Analysis vol.inpress, pp.inpress, 2016,
  4. Polymorphisms and Hepatocellular Carcinoma Risk: A Meta-Analysis vol.17, pp.11, 2013,
  5. Association between epidermal growth factor gene +61A/G polymorphism and the risk of hepatocellular carcinoma: a meta-analysis based on 16 studies vol.15, pp.1, 2015,